Candel Therapeutics (CADL) Earnings Analysis

Candel Therapeutics (CADL) next reports earnings on 2026-08-13, consensus EPS -0.22 USD. Last quarter (2026-05-14) it beat with EPS -0.14 USD vs -0.22 USD est (+36.4%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -10.26.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CADL next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.22 USD
Revenue estimaten/a

CADL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.14 USD-0.22 USD+36.4%Beat
2026-03-12-0.54 USD-0.24 USD-125%Miss
2025-11-13-0.21 USD-0.17 USD-23.5%Miss
2025-08-14-0.09 USD-0.17 USD+47.1%Beat
2025-03-13-0.4 USD-0.23 USD-73.9%Miss
2024-11-14-0.33 USDn/an/an/a

Beat rate: 2/5 (40%) over reported quarters with consensus data.

CADL valuation and analyst view

Trailing P/E-10.26
Trailing EPS-0.87268 USD
Price / book4.56
Dividend yield0.00%
Market cap0.55B
Analyst consensusBuy (9 buy / 1 hold / 0 sell)
Avg price target22 USD

Related research pages

Frequently asked questions

When is Candel Therapeutics (CADL)'s next earnings date?

Candel Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.22 USD.

Did CADL beat earnings last quarter?

In its 2026-05-14 report, CADL posted EPS of -0.14 USD versus a -0.22 USD estimate — a beat of 36.4%.

What is CADL's earnings track record?

Over the last 5 reported quarters with consensus data, CADL beat estimates 2 times (40%).

What is CADL's current P/E ratio and EPS?

CADL trades at a trailing P/E of -10.26 on trailing EPS of -0.8726803163155861 USD.

What do analysts rate CADL?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 22 USD.